The number of COVID-19 indicated medical devices gaining approval in Q2 2021 saw a 3% drop when compared with Q1 2021, according to GlobalData’s medical devices marketed products database
Compared with Q2 2020, the number of COVID-19 indicated medical devices gaining approval in Q2 2021 saw an 80% drop globally.
North America tops COVID-19 approved medical devices activity
Comparing COVID-19 medical device approvals activity in different regions of the globe, North America held the top position for approved products (44%) in Q2 2021, followed by Europe (35%), and Asia-Pacific (20%).
On a country level, the US had the most COVID-19 approved medical devices during the quarter, representing the largest share (32%) of the global market. In second place was Canada with a share of 17%, followed by Germany with 14%.
COVID-19 marketed medical devices: Development activity in Q2 2021
GlobalData’s database indicated that EUA marketed medical devices that addressed the COVID-19 pandemic accounted for 28% of medical devices in Q2 2021, compared with 33% in Q1 2021.
COVID-19 medical devices obtaining CE-IVD approval inclined to 13% in Q2 2021, compared with Q1 2021.
CE-IVD have become more common during the COVID-19 pandemic, as an expeditious mechanism to bring therapeutic devices to market more quickly than normal device approvals.
Company-developed COVID-19 medical devices lead in Q2 2021
GlobalData’s databases indicated that company-developed medical devices accounted for a 99% share of approved COVID-19 devices globally during Q2 2021, while institute-developed marketed products held the remaining share.
The quarterly average for Q2 2021 saw 99% of approved COVID-19 indicated devices originating from private and public companies, and 1% from institutes.
The Covid-19 medical devices approval data used in this article were extracted from Medical Marketed Products Database of GlobalData’s Medical Intelligence Center. Marketed Products database covers all commercialized medical devices which are intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. Marketed products are covered from regulatory bodies like US FDA, company websites, news releases, SEC filings etc. The information is collected by following systematic research techniques and proprietary methodology.